Dr Reddy's Semaglutide Injection Gets Canadian OK From Health Canada

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Dr Reddy's Semaglutide Injection Gets Canadian OK From Health Canada
Overview

Dr Reddy's Laboratories is moving forward with its semaglutide injection in Canada, having secured Drug Identification Numbers (DINs) from Health Canada. This regulatory step paves the way for potential approval and market launch. The company recently launched its injectable semaglutide, Obeda, for type 2 diabetes in India, following patent expiry.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Health Canada Steps Forward

Dr Reddy's Laboratories has confirmed receiving the necessary Drug Identification Numbers (DINs) for its semaglutide injection from Health Canada. This regulatory achievement signifies that the drug's core information and formulation have passed an initial review, a crucial step toward potential market approval in Canada.

Dialogue Continues for Launch

Company officials are actively engaged with Canadian regulators to navigate the final approval stages. Dr Reddy's aims to introduce its semaglutide product to Canadian patients pending final clearance. This development builds upon the company's recent expansion into the diabetes management market.

Leveraging India Strategy

In India, Dr Reddy's made history as the first domestic company to secure approval from the Drugs Controller General of India (DCGI) for generic semaglutide. This strategic market entry, timed precisely after patent expirations, has provided a strong foundation. The company is now looking to replicate this success and expand its global footprint for key therapeutic areas, with Canada representing a significant opportunity.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.